The National Pulmonary Hypertension Unit participates in numerous international multi-centre clinical trials for the treatment of PAH.
Click on participant information for further details on clinical trial involvement.
The PH program is also fortunate to have the ability to provide patients with an opportunity to receive new and innovative drugs to patients who meet specific criteria and on a named patient basis. Typically these drugs are not licensed as yet are undergoing the licensing process.
In addition to this, the unit is involved in several international data registries looking at different PH groups, outcomes, medical and surgical options and follow up. Patient identification is strictly confidential.